齐拉西酮和利培酮治疗精神分裂症的对照研究

A Comparative Study Between Zipraside and Risperidone in the Treatment of Schizophrenia

目的以利培酮为对照,探讨齐拉西酮治疗精神分裂症的疗效和安全性。方法将60例符合CCMD-3诊断标准的精神分裂症病人随机分为两组,分别给予齐拉西酮和利培酮治疗8周。于治疗前和治疗后l、2、4、8周末采用阳性症状和阴性症状量表(PANSS)评定临床疗效,副反应量表(TESS)评定副反应。结果治疗8周后,两组疗效近似(p>0.05),齐拉西酮组和利培酮组的有效率差异无显著性(p>0.05);齐拉西酮组的副反应发生率低于利培酮组,但差异无显著性(p>0.05)。利培酮组锥体外系副反应明显高于齐拉西酮组(p<0.05)。结论齐拉西酮对精神分裂症患者的疗效与利培酮相当,副作用较小。

Objective To investigate the clinical efficacy and side effects of zipraside in the treatment of schizophrenia. Methods A total of 60 patients met the criteria of CCMD - 3 for schizophrenia were randomly assigned to two group treated with zipraside or risperidone for 8 weeks. The Positive and Negative Symptoms Scale（PANSS） and Treatment Emergent Symptoms Scale（TESS） were used to evaluate efficacy and adverse effeets before treatment and at the end of 1St,2nd,4th and 8th week. Results The therapeutic efficacy in zipraside group was similar to that in risperidone group（p 〉 0.05 ） ,and there was no significant difference between the two groups（p 〉 O. 05 ）. Incidence of adverse effects in zipraside group was lower than that in risperidone group, but the difference was not significant （p 〉 0.05 ） ,The incidences of extrapyramidal symptoms in risperidone group were significantly higher than those in zipraside group. Conclusion zipraside is as effective as risperidone for treating schizophrenia with 1 ower side effects.